Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hi-Q Marine Biotech is a Taiwan-based marine biotechnology and consumer health company founded in 1998 that develops and commercializes seaweed-derived health products, especially low molecular weight fucoidan ingredients and branded supplements. The company originated in aquaculture and ecological recirculating aquaculture systems, then expanded into human health, skincare, pet health, and functional food applications. Its core differentiator is an extraction and bioprocessing capability for Oligo Fucoidan sourced from brown seaweed, which it markets under the Hi-Q brand and related ingredient branding. Hi-Q appears to operate as a revenue-generating commercial-stage company rather than a drug-development biotech, with products sold through its own channels and B2B ingredient supply. The business is healthcare-adjacent and life-science relevant, but its portfolio is centered on nutraceutical, wellness, and personal care products rather than regulated prescription therapeutics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HI-Q.